The Pereira group has pioneered cell fate reprogramming approaches in immunology with induced dendritic cells (Rosa et al, Science Immunology 2018; Rosa et al, Science Immunology 2022) and has shown recently that the same combination of factors can reprogram tumor cells into antigen presenting cells (Zimmermannova et al, In revision). 

This project will aim to test a cancer immunotherapy approach based on in-vivo dendritic cell reprogramming of tumor cells to reinstate anti-tumor immunity. 

Key requirements:

• PhD in immunology, immune-oncology, tumor immunology, or similar, recently graduated or with less than 3 years of post-graduation experience in academic or industrial environment.
• Documented knowledge in tumor immunology, with practical experience in in-vivo evaluation of cancer immunotherapies using mouse syngeneic mouse models.
• Further requirements include a strong publication record, very good communication skills, and oral and written proficiency in English.

Advantageous skills/knowledge:

• The candidate should be an enthusiastic and motivated scientist willing to join a dynamic collaborative project between academia and industry with translational focus.
• Practical experience with multiparametric flow cytometry, cell sorting and immunohistochemistry /immunofluorescence microscopy, or immunopeptidomics is a merit.
• Experience in dendritic cell biology and antigen presentation mechanisms is a merit, T cell biology is also attractive.
• Experience in analysis of RNA sequencing data and bioinformatics including R and/or Python is a merit.